# OnCo record paper-hurwitz-bevacizumab-crc-nejm-2004 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-hurwitz-bevacizumab-crc-nejm-2004/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-hurwitz-bevacizumab-crc-nejm-2004" ;
  schema:name "Hurwitz 2004: bevacizumab with chemotherapy for metastatic colorectal cancer, the first anti-angiogenic drug to extend life"@en ;
  schema:description "Adding the VEGF antibody bevacizumab to irinotecan-based chemotherapy prolonged survival in first-line metastatic colorectal cancer, the first time blocking a tumour's blood supply had been shown to help patients."@en ;
  schema:url <https://onco.cc/key-papers/paper-hurwitz-bevacizumab-crc-nejm-2004/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa032691> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa032691> ;
  schema:datePublished "2004"^^xsd:gYear ;
  schema:author "Hurwitz H, Fehrenbacher L, Novotny W, et al." ;
  onco:related <https://onco.cc/roadmaps/colorectal-roadmap/>, <https://onco.cc/key-papers/paper-van-cutsem-crystal-cetuximab-folfiri-nejm-2009/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:targets <https://onco.cc/targets/vegf/> ;
  onco:drugs <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/fluorouracil/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/os/>, <https://onco.cc/terms/pfs/> .